News of Note—Freenome bumps up series A to $72M; NxStage wins FDA nod for solo home dialysis

newspaper

> Freenome raised an additional $7 million in series A funding, bringing its total to $72 million. In March, the liquid biopsy player raised $65 million in a round led by Andreessen Horowitz. Release

> The FDA cleared NxStage’s system for solo home dialysis. Patients may now perform hemodialysis at home, without a care partner, during waking hours. Release

> MedGenome bagged $30 million in series C financing—the company will ramp up biomarker discovery programs and further the development of its OncoPept suite of immunotherapy biomarker solutions. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.